Abstract
Prion protein amyloid aggregates are associated with infectious neurodegenerative diseases, known as transmissible spongiform encephalopathies. Self-replication of amyloid structures by refolding of native protein molecules is the probable mechanism of disease transmission. Amyloid fibril formation and self-replication can be affected by many different factors, including other amyloid proteins and peptides. Mouse prion protein fragments 107-143 (PrP(107-143)) and 89-230 (PrP(89-230)) can form amyloid fibrils. -sheet core in PrP(89-230) amyloid fibrils is limited to residues ∼160–220 with unstructured N-terminus. We employed chemical kinetics tools, atomic force microscopy and Fourier-transform infrared spectroscopy, to investigate the effects of mouse prion protein fragment 107-143 fibrils on the aggregation of PrP(89-230). The data suggest that amyloid aggregates of a short prion-derived peptide are not able to seed PrP(89-230) aggregation; however, they accelerate the self-replication of PrP(89-230) amyloid fibrils. We conclude that PrP(107-143) fibrils could facilitate the self-replication of PrP(89-230) amyloid fibrils in several possible ways, and that this process deserves more attention as it may play an important role in amyloid propagation.
Highlights
Several neurodegenerative human health disorders, such as Alzheimer’s disease (AD) [1], Parkinson’s disease (PD) [2], as well as prion diseases [3] are all closely linked to a process, where particular proteins fail to maintain their native conformational state and form fibrillar amyloid aggregates possessing a cross-β structure
The aggregation reaction did not occur within reasonable experimental time (Appendix A Figure A2), the experimental conditions were modified to obtain rapid fibril elongation kinetics [34]
The addition of high amounts (10%) of PrP(107-143) fibrils into PrP(89-230) monomer solution had no effect on aggregation kinetics within the experimental time, whereas addition of even very low amounts (0.1%) of PrP(89-230) fibrils resulted in a substantial acceleration of aggregation reaction (Figure 1a,b)
Summary
Several neurodegenerative human health disorders, such as Alzheimer’s disease (AD) [1], Parkinson’s disease (PD) [2], as well as prion diseases [3] are all closely linked to a process, where particular proteins fail to maintain their native conformational state and form fibrillar amyloid aggregates possessing a cross-β structure. There are no cures or disease-modifying drugs available for most of these disorders, and even compounds that show promising results in vitro experience very high failure rates during clinical trials [4,8,9,10] Analysis of such failures revealed that the main factors preventing successful development of effective anti-amyloid drugs are the relatively poor understanding of amyloid aggregation mechanisms; the lack of knowledge of the specific species and aggregation step(s) that may be affected by the molecule in question; the lack of methods to monitor the aggregation reaction in a reliable manner [4,11]. There are two defined events related with amyloid fibril self-replication: fibril elongation and fibril surface-catalyzed nucleation (often referred to as secondary nucleation) [4,12,13,14,15]. Elongating fibrils usually replicate the structure of the initial seed (with only a couple of exceptions of possible conformational switching reported [16,17]); there is increasing evidence suggesting that the structure of amyloid fibrils replicated via secondary nucleation route is dependent on the environment rather than on the template of seeds [18,19,20,21]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.